Reduced elimination of cyclosporine a in elderly (>65 Years) kidney transplant recipients

Transplantation

Volumn 86, Issue 10, 2008, Pages 1379-1383

  Falck, Pål ^a   Åsberg, Anders ^a   Byberg, Karen Therese ^a   Bremer, Sara ^b   Bergan, Stein ^b   Reubsaet, Jan L E ^a   Midtvedt, Karsten ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cyclosporine A; Elderly patients; Pharmacokinetics; Renal transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; ABCB1 PROTEIN, HUMAN; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; CYCLOSPORIN; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; AGING; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; GERIATRIC PATIENT; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MORNING DOSAGE; PRIORITY JOURNAL; T LYMPHOCYTE; ADOLESCENT; BLOOD; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHYSIOLOGY; PILOT STUDY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; P-GLYCOPROTEIN; PILOT PROJECTS; PROSPECTIVE STUDIES; T-LYMPHOCYTES; YOUNG ADULT;

EID: 58149354277     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818aa4b6     Document Type: Article

References (28)

1. Mendonca HM, Dos Reis MA, de Castro de Cintra Sesso R, et al. Renal transplantation outcomes: A comparative analysis between elderly and younger recipients. Clin Transplant 2007; 21: 755.
2. Meier-Kriesche HU, OjoA,HansonJ,etal. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 2000; 69: 885.
3. de Fijter JW. The impact of age on rejection in kidney transplantation. Drugs Aging 2005; 22: 433.
4. Danovitch GM, Gill J, Bunnapradist S. Immunosuppression of the elderly kidney transplant recipient. Transplantation 2007; 84: 285.
5. Morales JM, Campistol JM, Andres A, et al. Immunosuppression in older renal transplant patients. Drugs Aging 2000; 16: 279.
6. Bernardo JF, McCauleyJ.Drug therapyintransplant recipients: Special considerations in the elderly with comorbid conditions. Drugs Aging 2004; 21: 323.
7. Meier-Kriesche HU, Kaplan B. Immunosuppression in elderly renal transplant recipients: Are current regimens too aggressive? Drugs Aging 2001; 18: 751.
8. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807.
9. Falck P, Asberg A, Guldseth H, et al. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation 2008; 85: 179.
10. Goldberg H, Ling V, Wong PY, et al. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 1988; 152: 552.
11. Berhanu D, Mortari F, De Rosa SC, et al. Optimized lymphocyte isolation methods for analysisofchemokine receptor expression. J Immunol Methods 2003; 279: 199.
12. Falck P, Guldseth H, Asberg A, et al. Determination of cyclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852: 345.
13. Katz DA, Grimm DR, Cassar SC, et al. CYP3A5 genotype has a dosedependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004; 75: 516.
14. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [erratum appears in Clin Pharmacol Ther 2004; 75:124]. Clin Pharmacol Ther 2001; 69: 169.
15. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668.
16. Nankivell BJ, Gruenewald SM, Allen RD, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
17. Barbari AG, Masri MA, Stephan AG, et al. Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: A prospective study. Exp Clin Transplant 2006; 4: 400.
18. Barbari AG, Masri MA, Stephan AG, et al. Cyclosporine lymphocyte maximum level: A new alternative for cyclosporine monitoring in kidney transplantation. Exp Clin Transplant 2005; 3: 293.
19. Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999; 15: 197.
20. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735.
21. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248.
22. SaekiT, UedaK, TanigawaraY, etal. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077.
23. Zanker B, Barth C, Menges AV, et al. Expression of the multidrug resistance gene MDR-1 in peripheral blood mononuclear cells from cyclosporine-treated renal transplant recipients rejecting their graft. Transplant Proc 1995; 27: 925.
24. Burckart GJ, Liu XI. Pharmacogenetics in transplant patients: Can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 2006; 28: 23.
25. Gotzl M, Wallner J, Gsur A, et al. MDR1 gene expression in lymphocytes of patients with renal transplants. Nephron 1995; 69: 277.
26. Donnenberg VS, Burckart GJ, Zeevi A, et al. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection. Transplantation 2004; 77: 1699.
27. Meaden ER, Hoggard PG, Khoo SH, et al. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 2002; 262: 159.
28. Parasrampuria DA, Lantz MV, Birnbaum JL, et al. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: A preliminary evaluation. J Clin Pharmacol 2002; 42: 304.